Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium (original) (raw)

The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were compared with that of vancomycin against clinical isolates of methicillin-susceptible and-resistant Staphylococcus aureus (n ‫؍‬ 200), coagulase-negative staphylococci (n ‫؍‬ 100), and vancomycin-susceptible and-resistant Enterococcus faecalis and Enterococcus faecium (n ‫؍‬ 50). Eperezolid and linezolid demonstrated good in vitro inhibitory activity, regardless of methicillin susceptibility for staphylococci (MIC at which 90% of the isolates are inhibited [MIC 90 ] range, 1 to 4 g/ml) or vancomycin susceptibility for enterococci (MIC 90 range, 1 to 4 g/ml). In time-kill studies, eperezolid and linezolid were bacteriostatic in action. A postantibiotic effect of 0.8 ؎ 0.5 h was demonstrated for both eperezolid and linezolid against S. aureus, S. epidermidis, E. faecalis, and E. faecium.